UroGen Pharma Ltd., a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, highlights the results of a sub-analysis from the first and largest post-commercial utilization review of JELMYTO® for pyelocalyceal solution presented at the American Urological Association Meeting 2023 in Chicago, IL.
